The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it.
I would like to know what people here actually do about BPC-157, as distinct from what is usually recommended. Those have diverged in every other subject I have looked at closely.
Mine is below, with the reasoning, including the parts I am not confident about.
Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.
Confirming post #3 from a second method, which matters more than confirming it from a second person.
Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.
Same conclusion as the reply above, reached differently, which is mildly reassuring.
On post #3 — agreed on the reasoning, with one qualification.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
That holds for the case as described. Change the assumptions and it may not.
The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.
Staff rationale: Hidden by community flags. Contained an unredacted laboratory report with identifiers visible (R12). The analytical content has been quoted back into the topic without them.
TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.
The corresponding entry is in the public moderation log. Hidden posts are never deleted.
The preclinical work is genuinely interesting and it is preclinical. A rodent tendon model is a model of a rodent tendon, and the translation record from that kind of model is poor.
The answer changed when I changed how I was measuring, which was informative.
Narrowing post #7, because the general version has more than one answer.
BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.
The mechanism is plausible, which is not the same as established.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Reading a preclinical wound-healing model and its relevance to a human tendon
On the subject in the title: Reading a preclinical wound-healing model and its relevance to a human tendon Working notes rather than a conclusion. Posting a small dataset on reading a preclinical…
|
+149 | 160 | 3.3k | 20mo |
|
TB-500 and thymosin beta-4: the fragment versus the protein
TB-500 and thymosin beta-4: the fragment versus the protein Writing it up because I had to work it out twice and would rather nobody else did. TB-500 and thymosin beta-4: what I expected, what I found, and…
|
+107 | 118 | 22k | 11mo |
|
Why plausible mechanism is not evidence of effect
Asking directly, because I could not find a straight answer: Why plausible mechanism is not evidence of effect What changes if the standard account of plausible mechanism is wrong? I ask because I have been…
|
+14 | 18 | 57k | 13mo |
|
BPC-157: what the rodent literature actually shows, and what it does not
BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I would like to know what people here actually do about BPC-157,…
|
+44 | 48 | 3k | 10mo |
|
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Reading a…
|
+64 | 69 | 27k | 4mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Preprint servers and what screening they do — the long version
On the subject in the title: Preprint servers and what screening they do — the long version Working notes rather than a conclusion. A preprint question rather than a question about the finding in it. The…
|
+7 | 11 | 26k | 4mo |
|
Reading a supplier's product description as a marketing document
On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…
|
+86 | 97 | 62k | 8mo |
|
Preprint servers and what screening they do
Preprint servers and what screening they do — setting out what I have, and where I think it stops being reliable. A preprint question rather than a question about the finding in it. The manuscript is on a…
|
+95 | 106 | 5.6k | 4mo |
|
A preprint whose numbers changed substantially at publication
A preprint whose numbers changed substantially at publication — setting out what I have, and where I think it stops being reliable. A preprint question rather than a question about the finding in it. The…
|
+90 | 95 | 21k | 9mo |
|
Citing a preprint in a maintained document: our rule and its reasoning — does this still hold?
The question in the title: Citing a preprint in a maintained document: our rule and its reasoning — does this still hold? I will give what I have already checked below so nobody repeats it. A question about…
|
+103 | 115 | 24k | 10mo |